While meeting up with some industry friends here at CBI’s 2nd Annual Bio/Pharmaceutical Emerging Media Optimization for Consumer-Focused Marketing conference, we talked a lot about Twitter. There’s also been a lot of debate about a recent addition the the Twitter-verse courtesy of Novo Nordisk. They recently launched Race with Insulin and promptly did something no other pharma company has ever done. They sent out a tweet with a pharma brand name. Here’s what their page looks like:

You’ll notice about the smallest fair balance fine print I’ve ever seen, but they’ve got it there. Their branded tweet was this:

After this went out, the industry bloggers promptly went into action. It was started by Ross Fetterolf, VP Digital Strategy at Ignite Health, who called this tweet “A Historic Day.” He closed his post with this: “I wonder if Charlie’s 125 followers have their Levemir flexpen’s primed and ready to inject along with Charlie when it’s time for his next dose. We’ll have to wait and see.” On the other hand, John Mack published a blog post about this tweet called: “Novo Nordisk’s Branded (Levemir) Tweet is Sleazy Twitter Spam!” He called the tweet nothing more than a “reminder ad.”   John further added: ”A reminder ad of any sort — whether in print, TV, Web, or Twitter — is, IMHO, a form of spam. I consider, therefore, Kimball’s unabashed product endorsement Tweet a particularly sleazy example of Twitter spam. We certainly do NOT want to see more Tweets like this and I disagree with Ross; I sincerely hope that this Tweet is NOT used as a “model” for other drug companies who want to adopt Twitter as a marketing vehicle.”

I’m with John here. But there’s been quite a lot of debate back and forth on this. Supporters of the tweet say that those with diabetes do talk about the brands they use all the time in everyday language, so this is normal for them. Others, like me, might agree with that, but don’t agree that any person would normally mention their drug’s generic name and where to find prescribing information. Can’t quite picture that coming up in conversation.

I’m fine with Novo Nordisk trying this. In fact, I applaud them for doing it. I also realize the realities of what can be tweeted and what can’t and how fair balance must be used. Debate continues on how pharma can do branded tweets that are even better. However, has anyone stopped to think that maybe, just maybe, this isn’t a feasible channel for pharma brand marketing? Maybe disease state information, but not branded information. John Mack also thought of this idea: “Charlie Kimball’s [the driver who Novo Nordisk sponsors] Tweets would be much more interesting if he stopped posting about cleaning his race suit, taking Levemir, etc, and told us a little bit about how he FEELs being a race car driver with diabetes, how he deals with the unique problems his medical condition gives him, etc. THAT would truly be inspirational!”

That I can get behind. The reality is that if you do have to include fair balance in every tweet, you can’t have authentic conversations, which is what Twitter is all about. Stop trying to get a brand message into everything, pharma friends. That’s not the answer to everything.

However, knowing that my comments or John’s are unlikely to dissuade the most determined pharma brand manager, those of us at the conference tried to think of a tool that pharma could use to Tweet without worrying about running into regulatory issues. Steve Woodruff came up with the big idea. Twegulate. Well, I couldn’t help but run with the idea, so I rushed back to the hotel and created it. Here it is for the first time anywhere…Twegulate:

What’s great about Twegulate is that Important Safety Information (ISI) is automatically included in every tweet. You can’t adjust it, you can’t delete it. Because the ISI is so long, it doesn’t leave many characters for the rest of the tweet, but you do get a full eight characters. You can use this to add updates such as: “Not much” “Hello” “Good Bye”. Not hugely engaging, but it’s a start.

Unfortunately, I don’t expect Twegulate to be launched anytime soon. We really don’t need it. As it stands now, pharma companies are doing it on their own with existing tools. Our automated tool probably doesn’t have a market. Oh well, so much for retiring this week.

Possibly related posts (auto-generated):

1. How to Avoid FDA Regulations Using Mobile Marketing
2. Crushing Pharma’s Digital Marketing Dreams–Part 2
3. Dose of Digital: The Year So Far